Balyasny Asset Management
CASC

Balyasny Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Balyasny Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30,040
Closed -$111K – 2546
2017
Q4 		$111K Buy
30,040
+7,646
+34% +$31.3K ﹤0.01% 1973
2017
Q3 		$92K Buy
+22,394
New +$85.7K ﹤0.01% 1787
2016
Q1 		– Sell
-5,692
Closed -$76K – 1665
2015
Q4 		$76K Buy
+5,692
New +$98K ﹤0.01% 1178

Balyasny Asset Management's CASC Position: Q1 2018 in Review

Balyasny Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 30,040 shares — an estimated $111K sold.

Balyasny Asset Management first reported a position in CASC in Q4 2015 and held it in 3 quarters. The position peaked at $111K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Balyasny Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 30,040 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $111K.
  • Balyasny Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • Balyasny Asset Management's Cascadian Therapeutics, Inc. position peaked at $111K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.